Blood Biomarkers Based Screening for HPV-driven OPC

NANot yet recruitingINTERVENTIONAL
Enrollment

10,000

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

January 31, 2032

Study Completion Date

January 31, 2032

Conditions
Head and Neck Squamous Cell CarcinomaAnal CancerHuman Papilloma Virus
Interventions
DIAGNOSTIC_TEST

HPV16-E6 serology and HPV ctDNA

"In the event of a malignant lesion identified on clinical examination and/or imaging, treatment will be performed according to the standard of care. In the absence of any suspicious lesion, but in the event of HPV ctDNA positivity, prophylactic surgery of the tonsils and base of the tongue (the vast majority of HPV-related OPC develop in these regions) will be proposed to the patient, given the high risk of OPC. In case of refusal of this prophylactic surgery, close clinical and imaging monitoring will be performed.~Surgical specimens will be analyzed to confirm or not the presence of HPV-driven OPC and HPV ctDNA will be measured post-operatively to ensure disease clearance."

All Listed Sponsors
lead

UNICANCER

OTHER